Literature DB >> 20070106

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.

Manthena V S Varma1, R Scott Obach, Charles Rotter, Howard R Miller, George Chang, Stefanus J Steyn, Ayman El-Kattan, Matthew D Troutman.   

Abstract

Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh). In this study, using a database comprised of Fa, Fg, Fh, and F values for 309 drugs in humans, an analysis of the interrelation of physicochemical properties and the individual parameters was carried out in order to define the physicochemical space for optimum human oral bioavailability. Trend analysis clearly indicated molecular weight (MW), ionization state, lipophilicity, polar descriptors, and free rotatable bonds (RB) influence bioavailability. These trends were due to a combination of effects of the properties on Fa and first-pass elimination (Fg and Fh). Higher MW significantly impacted Fa, while Fg and Fh decreased with increasing lipophilicity. Parabolic trends were observed for bioavailability with polar descriptors. Interestingly, RB has a negative effect on all three parameters, leading to its pronounced effect on bioavailability. In conclusion, physicochemical properties influence bioavailability with typically opposing effects on Fa and first-pass elimination. This analysis may provide a rational judgment on the physicochemical space to optimize oral bioavailability.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20070106     DOI: 10.1021/jm901371v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  42 in total

Review 1.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Authors:  Fabio Broccatelli; Caroline A Larregieu; Gabriele Cruciani; Tudor I Oprea; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2011-12-21       Impact factor: 15.470

Review 2.  The influence of the 'organizational factor' on compound quality in drug discovery.

Authors:  Paul D Leeson; Stephen A St-Gallay
Journal:  Nat Rev Drug Discov       Date:  2011-09-30       Impact factor: 84.694

3.  Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.

Authors:  Manthena V S Varma; Yurong Lai; Bo Feng; John Litchfield; Theunis C Goosen; Arthur Bergman
Journal:  Pharm Res       Date:  2012-05-26       Impact factor: 4.200

4.  Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Authors:  Manthena V Varma; Stefanus J Steyn; Charlotte Allerton; Ayman F El-Kattan
Journal:  Pharm Res       Date:  2015-07-09       Impact factor: 4.200

5.  Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS).

Authors:  Christian Maass; Cynthia L Stokes; Linda G Griffith; Murat Cirit
Journal:  Integr Biol (Camb)       Date:  2017-04-18       Impact factor: 2.192

6.  ALOHA: a novel probability fusion approach for scoring multi-parameter drug-likeness during the lead optimization stage of drug discovery.

Authors:  Derek A Debe; Ravindra B Mamidipaka; Robert J Gregg; James T Metz; Rishi R Gupta; Steven W Muchmore
Journal:  J Comput Aided Mol Des       Date:  2013-10-11       Impact factor: 3.686

7.  Structural and conformational determinants of macrocycle cell permeability.

Authors:  Björn Over; Pär Matsson; Christian Tyrchan; Per Artursson; Bradley C Doak; Michael A Foley; Constanze Hilgendorf; Stephen E Johnston; Maurice D Lee; Richard J Lewis; Patrick McCarren; Giovanni Muncipinto; Ulf Norinder; Matthew W D Perry; Jeremy R Duvall; Jan Kihlberg
Journal:  Nat Chem Biol       Date:  2016-10-17       Impact factor: 15.040

8.  Predicting the extent of metabolism using in vitro permeability rate measurements and in silico permeability rate predictions.

Authors:  Chelsea M Hosey; Leslie Z Benet
Journal:  Mol Pharm       Date:  2015-04-23       Impact factor: 4.939

9.  Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System.

Authors:  Ayman F El-Kattan; Manthena V Varma; Stefan J Steyn; Dennis O Scott; Tristan S Maurer; Arthur Bergman
Journal:  Pharm Res       Date:  2016-09-12       Impact factor: 4.200

10.  Activity and mRNA expression levels of selected cytochromes P450 in various sections of the human small intestine.

Authors:  Valérie Clermont; Alexia Grangeon; Azemi Barama; Jacques Turgeon; Michel Lallier; Jacques Malaise; Veronique Michaud
Journal:  Br J Clin Pharmacol       Date:  2019-04-13       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.